News Results

There are 369,077 News Results

Feb 7, 2024
Investigational targeted oral peptide JNJ-2113 demonstrated positive results in moderate-to-severe plaque psoriasis in Phase 2b study published in New England Journal of Medicine
Data from FRONTIER 1, a Phase 2b clinical trial, show JNJ-2113, the first and only targeted oral peptide that selectively blocks the IL-23 receptor, achieved the primary and all secondary...
Feb 13, 2024
InMode Reports Fourth Quarter and Full Year 2023 Financial Results; Quarterly Revenue of $126.8M and Record Full Year Revenue of $492M
YOKNEAM, Israel, Feb. 13, 2024 /PRNewswire/ --
Feb 20, 2024
Ceragon Reports 20% Growth in the Fourth Quarter of 2023; Exceeds Full-Year 2023 Guidance
Company Guides for Double Digit Growth; Targeting to Further Penetrate Private Network Markets
Feb 20, 2024
TECVAYLI® (teclistamab-cqyv) biweekly dosing approved by the U.S. FDA for the treatment of patients with relapsed or refractory multiple myeloma
Biweekly dosing with TECVAYLI(®), the first approved BCMA-targeting bispecific antibody, provides patients with dosing flexibility
Feb 20, 2024
CANOPY GROWTH TO HOLD SPECIAL MEETING OF SHAREHOLDERS
-- Shareholders to vote on the creation of a new class of Exchangeable Shares, which is expected to be a critical step in strategy to accelerate Canopy Growth's entry into...
Feb 21, 2024
Nevro Reports Fourth-Quarter and Full-Year 2023 Financial Results
Provides Full-Year and First-Quarter 2024 Guidance
Feb 22, 2024
Standard Motor Products, Inc. Releases Fourth Quarter and 2023 Year-End Results
NEW YORK, Feb. 22, 2024 /PRNewswire/ -- Standard Motor Products, Inc. (NYSE: SMP), a leading automotive parts manufacturer and distributor, reported today its consolidated financial results for the three and...
Feb 25, 2024
New England Journal of Medicine publishes Phase III data showing Xolair® (omalizumab) significantly reduced allergic reactions across multiple foods in people with food allergies
-- Detailed results from the NIH-sponsored Phase III OUtMATCH study showed treatment with Xolair increased the amount of peanuts, tree nuts, egg, milk and wheat that people as young as...
Feb 26, 2024
Equitable Breakthroughs in Medicine Development Reaches Next Phase Driving Diversity in Clinical Trials in Georgia, South Carolina, Tennessee, and Texas
EQBMED is a collaborative, community-based partnership to address diversity in clinical trials supported by grant funding from PhRMA NEW HAVEN, Conn., Feb. 26, 2024 /PRNewswire/ -- Equitable Breakthroughs in Medicine...
Feb 27, 2024
Syndax Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business Update
- BLA filing for axatilimab in chronic GVHD granted Priority Review; PDUFA action date set for August 28, 2024 -
36908

Pages

1

Stories of the day

Sep 9, 2025
Elbit Systems Launches Frontier: Next-Generation AI-Based System to Tackle...
Sep 9, 2025
Maxar Partners with Anduril to Power U.S Army’s Mixed-Reality Combat System
Sep 10, 2025
HENSOLDT offers Spexer radar as naval solution
Sep 10, 2025
QinetiQ’s Uncrewed Aerial Target milestone showcases sovereign capability